Oxford Biomedica plc (FRA:OXOA)
Germany flag Germany · Delayed Price · Currency is EUR
6.95
-0.05 (-0.71%)
At close: Dec 5, 2025

Oxford Biomedica Company Description

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.

The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties.

The Product segment is involved in the research and development of new gene therapeutic product candidates.

The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types.

The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996.

Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Oxford Biomedica plc
Country United Kingdom
Founded 1996
Industry Biological Products, Except Diagnostic Substances
Employees 850
CEO Frank Mathias

Contact Details

Address:
Windrush Court
Oxford, OX4 6LT
United Kingdom
Phone 44 1865 783 000
Website oxb.com

Stock Details

Ticker Symbol OXOA
Exchange Frankfurt Stock Exchange
Fiscal Year January - December
Reporting Currency GBP
SIC Code 2836

Key Executives

Name Position
Frank Mathias Chief Executive Officer
Lucinda Crabtree Chief Financial Officer
Thierry Cournez Chief Operating Officer
Sophia Bolhassan Head of Investor Relations